Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2010, Article ID 970580, 3 pages
http://dx.doi.org/10.1155/2010/970580
Case Report

Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome

1Ospedale Fatebenefratelli-Oftalmico, Corso di Porta Nuova 23, Milan, Italy
2Ospedale Vizzolo Predabissi, Via Pandina 1, Melegnano, Milano, Italy
3Ospedale San Raffaele, Università Vite e Salute, Via Olgettina 60, Milano, Italy

Received 29 March 2010; Accepted 25 October 2010

Academic Editor: Eric Eggenberger

Copyright © 2010 Paolo Milani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal detachment are well described; however, ideal therapy for such complication is unknown. Methods. One interventional case report is hereby described. A patient affected by macular serous neuroretinal detachment-complicated tilted disk syndrome underwent a complete ophthalmic examination. Optical coherence tomography and fluorescein angiography were taken at baseline and at scheduled visits. Two intravitreal treatments of bevacizumab (avastin, 1.25 mg/0.05 mL) were performed at monthly interval. Results. At scheduled visit, one month after the second injection, OCT depicted persistence of neuroretinal detachment. Best-corrected visual acuity remain stable as well as metamorphopsia and functional discomfort. Conclusion. Clinical evidence of this brief interventional case report indicates that one patient affected by recent serous macular detachment-complicated TDS did not benefit from 2 consecutive monthly intravitreal Avastin treatments. Best-corrected visual acuity remained stable over a total observation period of 6 months.